NCT05626322 2025-09-05Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaPfizerPhase 1/2 Terminated6 enrolled 17 charts
NCT05328102 2024-04-30Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)Xencor, Inc.Phase 2 Terminated3 enrolled 6 charts